Spyre Therapeutics
US-based Spyre Therapeutics develops precise immunology and therapeutic combinations for IBD and chronic inflammation.
Founded
2013US-based Spyre Therapeutics develops precise immunology and therapeutic combinations for IBD and chronic inflammation.
Spyre Therapeutics, Inc. is a biotechnology company based in the United States, founded with the mission to improve treatment options for Inflammatory Bowel Disease (IBD) and chronic inflammation diseases. The company focuses on developing best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches aimed at providing therapies with high efficacy and convenience for conditions such as ulcerative colitis (UC). Spyre Therapeutics is dedicated to addressing unmet medical needs within the IBD market.
The company boasts a team with extensive experience in developing and commercializing treatments. Notable affiliated individuals and investors have not been specified, but the company's achievements include advancing a robust pipeline of potential therapies. Spyre Therapeutics' impact lies in its innovative approach to treating IBD, aiming to significantly enhance the quality of life for patients through cutting-edge biotechnological solutions.
Companies similar to Spyre Therapeutics include Osprey Pharmaceuticals USA, Precision IBD, Sorriso Pharmaceuticals and Spyryx Biosciences.
Spyre Therapeutics was founded in 2013.
Spyre Therapeutics' headquarters is located in Austin, TX, US.
Spyre Therapeutics' most recent funding round was for $210M (USD) in June 2023.
As of Jun 22, 2023, Spyre Therapeutics has disclosed funding of $266M (USD). Undisclosed round amounts are excluded.
Spyre Therapeutics has 69 employees as of Feb 6, 2024.
Spyryx Biosciences
